Back to search

Article

A computational evaluation of FDA medicines' ability to inhibit Hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for Acute Respiratory Distress Syndrome.

2022-05-19

Abstract excerpt

<title>Abstract</title> <p>COVID-19 infection is associated with a significant fatality rate in individuals suffering from severe Acute Respiratory Distress Syndrome (ARDS). Among the several possibilities, inhibition of Hypoxia-inducible factor prolyl hydroxylase-2 or prolyl hydroxylase domain-containing protein 2 (PHD2) in a hypoxia independent way is a prospective therapeutic target for the treatment of ARDS....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8057ab4f-4ae3-5cb0-a2a9-51b67188a8b1
DOI
10.21203/rs.3.rs-1616269/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A computational evaluation of FDA medicines' ability to inhibit Hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for Acute Respiratory Distress Syndrome.DOI 10.21203/rs.3.rs-1616269/v1
Identification of novel TMPRSS2 inhibitors for COVID-19 using e-pharmacophore modelling, molecular docking, molecular dynamics and quantum mechanics studiesSemantic proximity
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugsSemantic proximity
Structural Insight into PRMT5 Inhibitors through Amalgamating Pharmacophore-Based Virtual Screening, ADME-Toxicity and Binding Energy Studies and Identify New Inhibitors by Molecular Docking.Semantic proximity
Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposingSemantic proximity
Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational directionSemantic proximity
Bioinformatics approaches to understand the interactions between the SARS corona Virus (SARS-CoV19) with stranded drugs of anti-retro viral treatment, Influenza and Malaria.Semantic proximity
Repurposing FDA-approved drugs against the “main protease” pivotal enzyme in COVID-19 virus using computer-aided drug design techniquesSemantic proximity
Combined Deep Learning and Molecular Docking Simulations Approach Identifies Potentially Effective FDA Approved Drugs for Repurposing Against SARS-CoV-2Semantic proximity
Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19Semantic proximity
Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?Semantic proximity
Binding site analysis of potential protease inhibitors of COVID-19 using AutoDockSemantic proximity
In Silico Elucidation of C- and N-Domain Selectivity of Dihydropyrimidinone Derivatives as Angiotensin-Converting Enzyme InhibitorsSemantic proximity
Select a neighboring publication to make it the new centre.